Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer

British Journal of Cancer

Volumn 89, Issue 6, 2003, Pages 977-982

  Bottini, A ^a   Berruti, A ^b   Brizzi, M P ^b   Bersiga, A ^a   Generali, D ^a   Allevi, G ^a   Aguggini, S ^a   Bolsi, G ^a   Bonardi, S ^a   Bertoli, G ^a   Alquati, P ^a   Dogliotti, L ^b  

^a Ist Osp   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; Haemoglobin; Predictive factors; Primary chemotherapy; Tumour response

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; KI 67 ANTIGEN; METHOTREXATE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE COUNT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROCYTE COUNT; FEMALE; FLUOROURACIL; HEMOGLOBINS; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; METHOTREXATE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141887360     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601216     Document Type: Article

References (36)

1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Molinterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: eight years experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100
2. Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, Aguggini S, Brunelli A, Betri E, Generali D, Scaratti L, Bertoli G, Alquati P, Dogliotti L (2002) Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 8: 1816-1821
3. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L (2000) p53 but not bcl2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758
4. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L (2001) Relationship between tumor shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85: 1106-1112
5. Canning MT, Postovit LM, Clarke SH, Graham CH (2001) Oxygen-mediated regulation of gelatinase and tissue inhibitor of metallo-proteinases-1 expression by invasive cells. Exp Cell Res 367: 88-94
6. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91: 2214-2221
7. Coleman CN, Mitchell JB, Camphausen K (2001) Tumor hypoxia; chicken, egg, or a piece of the pharm? J Clin Oncol 20: 610-615
8. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61: 1721-1733
9. Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-968
10. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer; experience from a large study with long-term follow-up. Histopathology 19: 403-410
11. Feldmann HJ (2001) Oxygenation of human tumors - implications for combined therapy. Lung Cancer 33(Suppl 1): S77-S83
12. Fisher B, Mamounas EP (1995) Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537-540
13. Fyles AW, Milosevic M, Wong R, Kavanagh PC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48: 149-156
14. Glaser CM, Millesi W, Kornek CV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705-715
15. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91
16. Graham CH, Forsdike J, Fitzerald CJ, Macdonald-Goodfellow S (1999) Hypoxia mediated stimulation of carcinoma cell invasiveness via up-regulation of urokinase receptor expression. Int J Cancer 80: 617-623
17. Green SL, Giaccia AJ (1998) Tumor hypoxia and cell cycle: implication for malignant progression and response to therapy. Cancer J Sci Am 4: 218-223
18. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634
19. Hamilton A, Piccart M (2000) The contribution of molecular markers to the prediction of response in the treatment of breast cancer. A review of the literature on HER-2, p53 and bcl-2. Ann Oncol 11: 647-663
20. Hockel M, Vaupel P (2001) Tumor hypoxia: definition and current clinical, biologic and molecular aspects. J Natl Cancer Inst 93: 266-271
21. Ikeda K, Kajiwara K, Tanabe E, Tokumaru S, Kishida E, Masuzawa Y, Kojo S (1999) Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells. Biochem Pharmacol 57: 1361-1365
22. Kovacs R, Wilhelm R, Heinrichsohn D (1998) Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin levels. Strahlenther Onkol 174: 128-132
23. Mamounas EP, Fisher B (2001) Preoperative (Neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 28: 389-399
24. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH (2001) Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 93: 1979-1885
25. McCarty Jr KS, Miller LS, Cox EB, Konrath J, McCarty KS (1985) Estrogen receptor analyses. Arch Pathol Lab Med 109: 716-721
26. Miller AB, Hoogstroten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
27. Pan S, Pederson L, Bachur NR (1981) Comparative flavoprotein catalysis of anthracycline antibiotic reductive cleavage and oxygen consumption. Mol Pharmacol 19: 184-186
28. Ravdin PM (2001) Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes. J Natl Cancer Inst Monogr 30: 80-84
29. Semenza GL (2001) Regulation of hypoxia induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 108: 39-40
30. Sevelda P, Gnant MF (2002) Influence of anemia on local relapse free survival of pre-menopausal primary breast cancer patients under adjuvant CMF chemotherapy: an analysis of the Austrian Breast Cancer Study Group. Proceedings of ASCO, May 18-21, 2002, Orlando, FL, p 65a [Meeting Abstract]
31. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970
32. Statsoft Inc. (1995) Statistica for Windows, Rel. 5.0. Tulsa, OK: Statsoft Inc.
33. Stohrer M, Boucher Y, Stangassinger M, Jain RK (2000) Oncotic pressure in solid tumors is elevated. Cancer Res 60: 4251-4255
34. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Belien JAM, de Waal RMW, van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumors. Eur J Cancer 38: 1564-1579
35. Wouters BG, Weppler SA, Koritzinsky M, Lauduyt W, Nuyts S, Theys J, Chiu RK, Lambin P (2002) Hypoxia as a target for combined modality treatments. Eur J Cancer 38: 240-257
36. Xu L, Xie K, Mukaida N, Mtsushima K, Fidler IJ (1999) Hypoxia-induced elevation of interleukin-8 expression by human ovarian carcinoma. Cancer Res 59: 5822-5829